Fundamental Analysis of UNIQURE NV(NASDAQ:QURE) stock

Fundamental Rating

QURE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 570 industry peers in the Biotechnology industry. QURE has a bad profitability rating. Also its financial health evaluation is rather negative. QURE is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

QURE had negative earnings in the past year.

QURE had a negative operating cash flow in the past year.

QURE had negative earnings in 4 of the past 5 years.

In the past 5 years QURE reported 4 times negative operating cash flow.

1.2 Ratios

QURE has a Return On Assets of -37.09%. This is in the better half of the industry: QURE outperforms 60.49% of its industry peers.

QURE has a worse Return On Equity (-429.05%) than 78.48% of its industry peers.

		Industry Rank	Sector Rank
ROA	-37.09%
ROE	-429.05%
ROIC	N/A

ROA(3y)-4.78%

ROA(5y)-15.75%

ROE(3y)-39.95%

ROE(5y)-41.91%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

QURE has a Gross Margin of 7.15%. This is in the better half of the industry: QURE outperforms 73.90% of its industry peers.

The Profit Margin and Operating Margin are not available for QURE so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	7.15%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

QURE does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, QURE has more shares outstanding

QURE has more shares outstanding than it did 5 years ago.

The debt/assets ratio for QURE is higher compared to a year ago.

2.2 Solvency

QURE has an Altman-Z score of -2.19. This is a bad value and indicates that QURE is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -2.19, QURE is in line with its industry, outperforming 50.62% of the companies in the same industry.

A Debt/Equity ratio of 8.56 is on the high side and indicates that QURE has dependencies on debt financing.

QURE has a worse Debt to Equity ratio (8.56) than 84.13% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	8.56
Debt/FCF	N/A
Altman-Z	-2.19

ROIC/WACCN/A

WACC7.31%

2.3 Liquidity

A Current Ratio of 6.51 indicates that QURE has no problem at all paying its short term obligations.

QURE has a Current ratio of 6.51. This is in the better half of the industry: QURE outperforms 64.90% of its industry peers.

QURE has a Quick Ratio of 6.51. This indicates that QURE is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of QURE (6.51) is better than 65.08% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	6.51
Quick Ratio	6.51

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

QURE shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.25%.

QURE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -74.43%.

The Revenue has been growing slightly by 6.99% on average over the past years.

EPS 1Y (TTM)-3.25%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%51.6%

Revenue 1Y (TTM)-74.43%

Revenue growth 3Y-24.96%

Revenue growth 5Y6.99%

Sales Q2Q%62.54%

3.2 Future

Based on estimates for the next years, QURE will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.58% on average per year.

QURE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 66.81% yearly.

EPS Next Y35.59%

EPS Next 2Y23.22%

EPS Next 3Y17.58%

EPS Next 5Y9.58%

Revenue Next Year86.49%

Revenue Next 2Y34.11%

Revenue Next 3Y61.29%

Revenue Next 5Y66.81%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for QURE. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QURE. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

QURE's earnings are expected to grow with 17.58% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y23.22%

EPS Next 3Y17.58%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for QURE!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

UNIQURE NV

NASDAQ:QURE (12/4/2024, 8:06:45 PM)

After market: 6.29 0 (0%)

6.29

-0.12 (-1.87%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap306.57M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-37.09%
ROE	-429.05%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	7.15%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.04

Health

		Industry Rank	Sector Rank
Debt/Equity	8.56
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	6.51
Quick Ratio	6.51
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-3.25%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y35.59%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-74.43%

Revenue growth 3Y-24.96%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

UNIQURE NV (QURE)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens